CSL Layoffs Set to Shake up 15% of Its Global Workforce

The US may be riddled with layoff announcements, but it isn’t the only region undergoing considerable changes in 2025. Australian biotechnology firm CSL has announced layoffs among its workforce, with major reorganization efforts expected to alter the makeup of the business. CSL is set to lay off 15% of its global workforce, along with plans to spin off its flu vaccine arm, Seqirus, by early 2026. 

Known as the world’s second-largest influenza vaccine maker and Australia’s fourth-largest company, CSL’s decision has stunned investors and employees alike, sending the company’s shares plunging over 15%. The decision comes amidst shifting sentiments regarding vaccines in the US, which the CEO referred to as “highly irrational” softness in the region. Despite the company’s 14% jump in annual profit, CSL’s workforce cuts have largely overshadowed any conversation regarding its strong performance.

Read more here.